Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was
conducted to investigate the efficacy and safety of deferasirox in patients aged ≥ 18 years
with transfusion-dependent iron overload.
The objective of this extension study is to assess the long-term safety of deferasirox and to
provide treatment in patients with transfusional iron overload.